Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TINCR (Terminal differentiation-induced non-coding RNA) is a long intergenic non-coding RNA (lincRNA), specifically classified as a lncRNA, implicated primarily in the regulation of epidermal differentiation and tissue development[1][2]. Unlike classical protein-coding targets, TINCR exerts its function at the RNA level: it acts as a scaffold for RNA-binding proteins, such as Staufen1, and promotes the post-transcriptional stabilization and accumulation of mRNAs needed for epidermal differentiation, predominantly by interacting with the TINCR box motif on target mRNAs[1]. TINCR does not encode a functional receptor, enzyme, or protein target; instead, it operates as an RNA molecule regulating gene expression and cell fate via epigenetic and post-transcriptional mechanisms. Dysregulation or altered expression of TINCR has been reported in certain cancers and may serve as a tissue-specific biomarker[2][3]. There is currently no evidence of direct drug interaction or targeting of TINCR, and its mechanism represents RNA-based scaffolding and regulatory functions rather than conventional "therapeutic target" activity[1][2]. **Essential context:** - TINCR is not a protein, receptor, kinase, transporter, or enzyme but a non-coding RNA[1][2]. - Its most widely accepted role is in skin/epidermal biology, specifically driving terminal differentiation by stabilizing differentiation-aiding mRNAs in the cytoplasm[1]. - Although associated with cancer biology in some studies, it is not directly targeted by drugs nor is it established as a validated clinical target. - Aliases like "TINCR ubiquitin domain containing" and "TINCR-encoded ubiquitin-like protein" are misleading, as TINCR’s function is as a non-coding RNA, not a ubiquitin-like protein. - TINCR is best referred to using its canonical lncRNA designation, and not as a protein target. **Limitations:** - No direct pharmacology, mechanism of action for drugs, or established safety concerns have been reported. - May be considered as a biomarker in some tissues or cancers but is not a clinical therapeutic target at present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Terminal differentiation-induced non-coding RNA (TINCR).